Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.
Chung HC, Kang YK, Chen Z, Bai Y, Wan Ishak WZ, Shim BY, Park YL, Koo DH, Lu J, Xu J, Chon HJ, Bai LY, Zeng S, Yuan Y, Chen YY, Gu K, Zhong WY, Kuang S, Shih CS, Qin SK. Chung HC, et al. Among authors: shim by. Cancer. 2022 Mar 1;128(5):995-1003. doi: 10.1002/cncr.34019. Epub 2021 Dec 8. Cancer. 2022. PMID: 34878659 Free PMC article. Clinical Trial.
A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.
Kim SJ, Kim JS, Kim SC, Kim YK, Kim YK, Kang JY, Yoon HK, Song JS, Lee SH, Moon HS, Kim JW, Kim KH, Kim CH, Shim BY, Kim HK. Kim SJ, et al. Among authors: shim by. Lung Cancer. 2010 Jun;68(3):446-9. doi: 10.1016/j.lungcan.2009.07.002. Epub 2009 Aug 14. Lung Cancer. 2010. PMID: 19683359 Clinical Trial.
A multicenter phase II study of belotecan, a new camptothecin analogue, in elderly patients with previously untreated, extensive-stage small cell lung cancer.
Yeo CD, Lee SH, Kim JS, Kim SJ, Kim SC, Kim YK, Kang HH, Yoon HK, Song JS, Moon HS, Kim JW, Kim KH, Shim BY, Kim CH. Yeo CD, et al. Among authors: shim by. Cancer Chemother Pharmacol. 2013 Oct;72(4):809-14. doi: 10.1007/s00280-013-2256-0. Epub 2013 Aug 6. Cancer Chemother Pharmacol. 2013. PMID: 23918044 Clinical Trial.
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
Cheng AL, Cornelio G, Shen L, Price T, Yang TS, Chung IJ, Dai GH, Lin JK, Sharma A, Yeh KH, Ma B, Zaatar A, Guan Z, Masood N, Srimuninnimit V, Yau T, Gibbs P, Wang X, Doval DC, Oh ST, Shim BY, Gorospe C, Wang HM, Sirachainan E, Hill A, Suh KW, Beier F, Chatterjee S, Lim R. Cheng AL, et al. Among authors: shim by. Clin Colorectal Cancer. 2017 Jun;16(2):e73-e88. doi: 10.1016/j.clcc.2016.08.005. Epub 2016 Sep 7. Clin Colorectal Cancer. 2017. PMID: 27780749 Free article. Clinical Trial.
80 results